Improvement in Ulcerative Colitis by Administration of Benralizumab for Comorbid Refractory Bronchial Asthma: A Novel Clinical Observation. Issue 1 (19th August 2020)

• Record Type: Journal Article
• Authors: Sugimoto, Ken; Fujita, Shoya; Miyazu, Takahiro; Ishida, Natsuki; Tani, Shinya; Yamade, Mihoko; Hamaya, Yasushi; Iwaizumi, Moriya; Furuta, Takahisa; Osawa, Satoshi
• Is Part Of: Inflammatory bowel diseases. Volume 27:Issue 1(2021)
• Page Start: e3
• Page End: e4
• Publication Date: 2020-08-19
• Subjects: Inflammatory bowel diseases -- Periodicals; Colitis, Ulcerative -- Periodicals; Crohn Disease -- Periodicals; Inflammatory Bowel Diseases -- Periodicals; 616.344
• DOI: 10.1093/ibd/izaa225
• Languages: English
• ISSNs: 1078-0998

Abstract

Abstract : We present a case of ulcerative colitis improved through benralizumab, which binds to the eosinophil IL-5 receptor and the Fcy receptor on natural killer cells, inducing antibody-dependent cell-mediated cytotoxicity, causing apoptosis, and directly removing eosinophils, in treating comorbid refractory bronchial asthma.